JP6805336B2 - 薬学的組み合わせ - Google Patents

薬学的組み合わせ Download PDF

Info

Publication number
JP6805336B2
JP6805336B2 JP2019515782A JP2019515782A JP6805336B2 JP 6805336 B2 JP6805336 B2 JP 6805336B2 JP 2019515782 A JP2019515782 A JP 2019515782A JP 2019515782 A JP2019515782 A JP 2019515782A JP 6805336 B2 JP6805336 B2 JP 6805336B2
Authority
JP
Japan
Prior art keywords
compound
cancer
braf
fluoro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525948A5 (enExample
JP2019525948A (ja
Inventor
ジョルダーノ キャポニグロー
ジョルダーノ キャポニグロー
チュー アレクサンダー カオ
チュー アレクサンダー カオ
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
アレイ バイオファーマ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6805336(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アレイ バイオファーマ、インコーポレイテッド, アレイ バイオファーマ、インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2019525948A publication Critical patent/JP2019525948A/ja
Publication of JP2019525948A5 publication Critical patent/JP2019525948A5/ja
Application granted granted Critical
Publication of JP6805336B2 publication Critical patent/JP6805336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2019515782A 2016-06-03 2017-06-02 薬学的組み合わせ Active JP6805336B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03
US62/345,389 2016-06-03
PCT/US2017/035653 WO2017210538A1 (en) 2016-06-03 2017-06-02 Pharmaceutical combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020201152A Division JP2021054832A (ja) 2016-06-03 2020-12-03 薬学的組み合わせ

Publications (3)

Publication Number Publication Date
JP2019525948A JP2019525948A (ja) 2019-09-12
JP2019525948A5 JP2019525948A5 (enExample) 2020-05-28
JP6805336B2 true JP6805336B2 (ja) 2020-12-23

Family

ID=60477982

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515782A Active JP6805336B2 (ja) 2016-06-03 2017-06-02 薬学的組み合わせ
JP2020201152A Pending JP2021054832A (ja) 2016-06-03 2020-12-03 薬学的組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020201152A Pending JP2021054832A (ja) 2016-06-03 2020-12-03 薬学的組み合わせ

Country Status (26)

Country Link
US (3) US10485788B2 (enExample)
EP (1) EP3463345B1 (enExample)
JP (2) JP6805336B2 (enExample)
KR (1) KR102439911B1 (enExample)
CN (1) CN109890386B (enExample)
AU (1) AU2017275650B2 (enExample)
BR (1) BR112018074941A2 (enExample)
CA (1) CA3026361A1 (enExample)
CL (1) CL2018003421A1 (enExample)
CO (1) CO2019000010A2 (enExample)
CR (1) CR20190002A (enExample)
DK (1) DK3463345T3 (enExample)
FI (1) FI3463345T3 (enExample)
HU (1) HUE060653T2 (enExample)
IL (1) IL263431A (enExample)
MA (1) MA45187A (enExample)
MX (1) MX387795B (enExample)
PH (1) PH12018502549A1 (enExample)
PL (1) PL3463345T3 (enExample)
PT (1) PT3463345T (enExample)
RU (1) RU2759669C2 (enExample)
SG (1) SG11201810793XA (enExample)
SI (1) SI3463345T1 (enExample)
UA (1) UA125436C2 (enExample)
WO (1) WO2017210538A1 (enExample)
ZA (1) ZA201900019B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
JP7676371B2 (ja) 2019-10-11 2025-05-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 薬剤用量決定デバイスおよび方法
EP4103286A4 (en) * 2020-02-10 2024-03-20 Cedars-Sinai Medical Center METHOD OF TREATMENT OF PANCREATIC CANCER
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
JP2025541200A (ja) * 2022-12-15 2025-12-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん処置のための併用療法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
AU2012267888A1 (en) * 2011-06-07 2014-01-30 Caris Mpi, Inc. Molecular profiling for cancer
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
IN2015DN00450A (enExample) * 2012-08-07 2015-06-26 Novartis Ag
CA3079071C (en) * 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same
JP2016503399A (ja) * 2012-10-25 2016-02-04 ノバルティス アーゲー 組合せ
US9913844B2 (en) 2013-03-21 2018-03-13 Novartis Ag Combination therapy
WO2015008729A1 (ja) 2013-07-18 2015-01-22 株式会社ダイセル 酸化物の製造方法
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
BR112016011222A2 (pt) * 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
US10323035B2 (en) * 2015-04-01 2019-06-18 Crystal Pharmatech Co., Ltd. Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
WO2017019279A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas

Also Published As

Publication number Publication date
AU2017275650A1 (en) 2019-01-17
CN109890386B (zh) 2022-05-24
MX387795B (es) 2025-03-19
RU2018146812A3 (enExample) 2020-10-09
PH12018502549A1 (en) 2019-04-08
US11376239B2 (en) 2022-07-05
PL3463345T3 (pl) 2023-02-06
CN109890386A (zh) 2019-06-14
CO2019000010A2 (es) 2019-05-21
RU2018146812A (ru) 2020-07-09
IL263431A (en) 2019-01-31
SI3463345T1 (sl) 2023-02-28
KR102439911B1 (ko) 2022-09-05
DK3463345T3 (da) 2023-01-09
CA3026361A1 (en) 2017-12-07
FI3463345T3 (fi) 2023-01-31
BR112018074941A2 (pt) 2019-03-12
EP3463345A1 (en) 2019-04-10
CL2018003421A1 (es) 2019-07-19
UA125436C2 (uk) 2022-03-09
MX2018014973A (es) 2019-12-18
HUE060653T2 (hu) 2023-04-28
US20200230108A1 (en) 2020-07-23
US20190105303A1 (en) 2019-04-11
JP2021054832A (ja) 2021-04-08
MA45187A (fr) 2019-04-10
SG11201810793XA (en) 2018-12-28
KR20190119507A (ko) 2019-10-22
EP3463345B1 (en) 2022-11-02
AU2017275650B2 (en) 2023-06-01
PT3463345T (pt) 2023-01-06
US20230044943A1 (en) 2023-02-09
WO2017210538A1 (en) 2017-12-07
ZA201900019B (en) 2023-04-26
JP2019525948A (ja) 2019-09-12
EP3463345A4 (en) 2020-02-26
RU2759669C2 (ru) 2021-11-16
US10485788B2 (en) 2019-11-26
CR20190002A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
JP2021054832A (ja) 薬学的組み合わせ
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN119907671A (zh) Kras g12c抑制剂给药方案
US20180353602A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
TW202416986A (zh) 使用ｕｌｋ抑制劑治療病症之方法
TW202342047A (zh) 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
TW202304438A (zh) 使用貝伐拉非尼及考比替尼或使用貝伐拉非尼、考比替尼及阿替利珠單抗的組合療法
US20260027117A1 (en) Methods of treating small cell lung cancer
JP2025530296A (ja) 転移性癌を治療するためのｐｌｋ１阻害剤と抗血管新生剤の併用
US20230097085A1 (en) [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
TW202317125A (zh) 治療癌症之方法
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
US20230102483A1 (en) [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
US20240307392A1 (en) Erk1/2 and egfr inhibitors combination therapy
TW202535407A (zh) 治療癌症的方法
TW202404600A (zh) 使用ptpn11抑制劑及pd-1/pd-l1抑制劑之組合療法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200414

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200414

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201203

R150 Certificate of patent or registration of utility model

Ref document number: 6805336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250